Johanna Friedl-Naderer

Johanna Friedl-Naderer

Chief Commercial OfficeratDyne Therapeutics· In proxies 2024–2025

Pay in FY2025-87% from the year before · Dyne Therapeutics stock -17.0% the same year

Johanna Friedl-Naderer was paid $1.1M in FY2025 (Dec), down 87%. Dyne Therapeutics stock fell 17.0% that year.

Pay$100 in the stock at the end of FY23 → $147
Pay is from the Summary Compensation Table of each Dyne Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Dyne TherapeuticsPublic company · 2 yr
    • Chief Commercial Officer2024 – Present · 2 yrStock in role +34%
  2. Pharmaceutical Industries & AssociationsPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?